Table 3.
Clinical characteristics of Fabry registry patients grouped by baseline eGFR values
| eGFR |
P | |||
|---|---|---|---|---|
| ≥90 | <90 to ≥60 | <60 | ||
| Men | ||||
| number of male patients, N | 68 | 36 | 17 | |
| eGFRa at baseline, mean SD) | 109 (13.3) | 78 (8.6) | 42 (13.7) | |
| age at baseline eGFR, mean (SD), years | 30 (9.4) | 37 (12.5) | 47 (16.1) | <0.0001 |
| men with baseline UP/Cr data, n | 29 | 12 | 7 | |
| UP/Cr, baseline mean (SD) | 0.9 (1.0) | 1.5 (1.4) | 1.8 (1.3) | NS |
| median (25th, 75th) | 0.6 (0.2, 1.1) | 1.3 (0.6, 1.8) | 1.5 (0.8, 3.5) | |
| men with averaged UP/Cr data, n | 68 | 36 | 17 | |
| UP/Cr, averaged mean (SD) | 0.8 (0.7) | 1.3 (1.3) | 1.9 (1.6) | 0.0025 |
| median (25th, 75th) | 0.6 (0.2, 1.2) | 0.9 (0.1, 1.9) | 1.5 (1.1, 2.2) | |
| BP, n | 63 | 34 | 11 | |
| averaged systolic BP (median, 25th, 75th), mmHg | 128 (120, 137) | 126 (114, 132) | 122 (118, 134) | NS |
| averaged diastolic BP (median, 25th, 75th), mmHg | 77 (72, 84) | 77 (72, 82) | 72 (70, 78) | NS |
| reported history of ACEi/ARB use, n (%) | 12 (18) | 9 (25) | 5 (29) | NS |
| Women | ||||
| number of female patients, N | 210 | 114 | 17 | |
| eGFRa at baseline, mean (SD) | 109 (11.6) | 76 (8.0) | 47 (8.8) | |
| age at baseline eGFR, mean (SD), years | 35 (11.3) | 46 (10.7) | 59 (11.7) | <0.001 |
| women with baseline UP/Cr data, n | 109 | 59 | 10 | |
| UP/Cr, baseline mean (SD) | 0.7 (0.9) | 0.8 (1.1) | 2.5 (2.1) | 0.004 |
| median (25th, 75th) | 0.2 (0.1, 0.9) | 0.5 (0.1, 1.0) | 2.1 (0.5, 4.2) | |
| women with averaged UP/Cr data, n | 210 | 114 | 17 | |
| UP/Cr, averaged mean (SD) | 0.7 (0.9) | 1.0 (1.4) | 1.8 (1.9) | 0.002 |
| median (25th, 75th) | 0.2 (0.1, 0.9) | 0.4 (0.1, 1.4) | 1.0 (0.3, 2.9) | |
| BP, n | 196 | 110 | 16 | |
| averaged systolic BP (median, 25th, 75th), mmHg | 119 (111, 129) | 125 (113, 135) | 138 (131, 144) | <0.0001 |
| averaged diastolic BP (median, 25th, 75th), mmHg | 74 (68, 80) | 77 (70, 83) | 84 (74, 90) | 0.003 |
| reported history of ACEi/ARB use, n (%) | 34 (16) | 21 (18) | 9 (53) | 0.008 |
“Averaged” data reflect the average of all values reported within 6 months of the date of the first eGFR assessment to the most recent assessment. P values were calculated by the Kruskal-Wallis test; NS, not significant.
a
eGFR data are expressed as ml/min per 1.73 m2.